PMID- 16406411
OWN - NLM
STAT- MEDLINE
DCOM- 20070730
LR  - 20131121
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 103
IP  - 3
DP  - 2006 Feb 20
TI  - Antidiabetic effects of dietary administration of Aloe arborescens Miller 
      components on multiple low-dose streptozotocin-induced diabetes in mice: 
      investigation on hypoglycemic action and systemic absorption dynamics of aloe 
      components.
PG  - 468-77
AB  - We carried out three experimental trials to determine antidiabetic effects of 
      Aloe arborescens Miller components. Firstly, ICR mice which received frequent 
      injections of streptozotocin (Sz) in small doses (low-dose Sz-induced diabetes 
      mice) were fed ad libitum with basal diets supplemented with components of Aloe 
      arborescens Miller var. natalensis Berger (Kidachi aloe) and Aloe vera Linne from 
      31 days before to 73 days after the Sz injections. Variation in blood glucose 
      levels, incidence rates of insulitis and blood insulin levels were examined 
      during the trial. As a result, groups receiving diets supplemented at the rate of 
      2% with whole leaf of Kidachi aloe and 10 KDa fraction powder (a fraction with 
      less than 10 KDa molecular weight derived from Kidachi aloe leaf skin juice by 
      ultra filtration) significantly suppressed the elevation of blood sugar as 
      compared to a control group receiving basal diet. In contrast, there was no 
      significant effect with Aloe vera leaf pulp powder. Insulitis emerged at the rate 
      of 87% in the basal diet group. On the contrary, the whole aloe leaf and 10 KDa 
      fraction groups significantly decreased the incidence of insulitis and incidence 
      rates of whole aloe leaf and 10 KDa fraction powder were 51 and 38%, 
      respectively. While insulin levels in the basal diet group averaged at 0.05 ng, 
      more than four times the insulin level was observed in the 10 KDa group relative 
      to the basal diet group. Secondary, the inhibitory effects of test materials on 
      intestinal glucose absorption were observed using the jejunum of rats. A strong 
      inhibitory action on intestinal glucose absorption was observed in the 10 KDa 
      fraction powder group. Thirdly, phenol compounds derived from aloe in the blood 
      serum and organs were quantitatively measured by a HPLC following forced 
      administration of aloe components to rats to determine absorption kinetics of 
      aloe components inside the body. The primary component of aloe phenol compounds 
      is the same component of the 10 KDa fraction powder and it was found in the 
      pancreas and liver in addition to in the blood serum. The above results indicate 
      that fore and aft when Sz injections could cause selective toxicity to B cells of 
      islets, the dietary administration of 10 KDa fraction powder to mice would lead 
      to the persistence of aloe phenol compound having an antioxidant activity in the 
      pancreas and blood, which could protect islets of Langerhans from the destruction 
      caused by methyl radical derived from Sz. The results also suggested the 
      possibility of the 10 KDa fraction powder to alleviate the burden of insulin 
      secretion as it has an inhibitory action on glucose absorption in the jejunum of 
      rats.
FAU - Beppu, Hidehiko
AU  - Beppu H
AD  - Fujita Memorial Nanakuri Institute, Fujita Health University, 1865 Isshiki-cho, 
      Hisai, Mie 514-1296, Japan. hbeppu@fujita-hu.ac.jp
FAU - Shimpo, Kan
AU  - Shimpo K
FAU - Chihara, Takeshi
AU  - Chihara T
FAU - Kaneko, Takaaki
AU  - Kaneko T
FAU - Tamai, Ikuko
AU  - Tamai I
FAU - Yamaji, Sachiyo
AU  - Yamaji S
FAU - Ozaki, Sayaka
AU  - Ozaki S
FAU - Kuzuya, Hiroshi
AU  - Kuzuya H
FAU - Sonoda, Shigeru
AU  - Sonoda S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060106
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anthracenes)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Plant Extracts)
RN  - 1415-73-2 (barbaloin)
RN  - 38412-46-3 (aloenin)
RN  - KA46RNI6HN (Emodin)
SB  - IM
MH  - *Aloe
MH  - Animals
MH  - Anthracenes/pharmacokinetics
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Experimental/*blood/pathology/prevention & control
MH  - Diet
MH  - Emodin/pharmacokinetics
MH  - Female
MH  - Glucosides/pharmacokinetics
MH  - Hypoglycemic Agents/administration & dosage/pharmacokinetics/*pharmacology
MH  - Insulin/blood
MH  - Intestinal Absorption
MH  - Islets of Langerhans/drug effects/pathology
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Plant Extracts/administration & dosage/pharmacokinetics/*pharmacology
MH  - Plant Leaves
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rats, Wistar
MH  - Tissue Distribution
EDAT- 2006/01/13 09:00
MHDA- 2007/07/31 09:00
CRDT- 2006/01/13 09:00
PHST- 2005/01/05 00:00 [received]
PHST- 2005/09/26 00:00 [revised]
PHST- 2005/10/26 00:00 [accepted]
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2007/07/31 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - S0378-8741(05)00780-4 [pii]
AID - 10.1016/j.jep.2005.10.034 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2006 Feb 20;103(3):468-77. doi: 10.1016/j.jep.2005.10.034. Epub 
      2006 Jan 6.